Nine Drug Giants Accept Trump’s ‘Most-Favored-Nation’ Pricing in Exchange for Tariff Relief

Washington has flirted with drug-price equalisation before—Jimmy Carter’s 1978 Hospital Cost Containment Act failed, and the 2003 Medicare Part D law explicitly barred price negotiations—but nothing this explicit since Nixon’s 1971 wage-price controls. Linking U.S. prices to the ‘cheapest abroad’ turns the post-WWII model on its head: for decades high American prices financed global R&D while Europe imposed reference pricing. Like Reagan’s 1984 Semiconductor Pact or Biden’s 2021 CHIPS Act, the tariff-for-investment swap also signals a return to muscular industrial policy aimed at onshoring strategic supply chains. If these deals hold, they may erode the cross-subsidy that has long funded innovation, forcing either new R&D incentives or slower drug pipelines over the next half-century; if they unravel, the episode will read like Nixon’s temporary price freeze—spectacular headline, modest lasting effect. Either way, it marks another step in the century-long oscillation between laissez-faire healthcare pricing and government intervention in the world’s largest drug market.